Brandywine Global Investment Management LLC Sells 7,064 Shares of Pfizer Inc. (NYSE:PFE)

Brandywine Global Investment Management LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 0.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,209,135 shares of the biopharmaceutical company’s stock after selling 7,064 shares during the quarter. Brandywine Global Investment Management LLC’s holdings in Pfizer were worth $32,078,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of PFE. United Bank increased its position in Pfizer by 3.7% in the third quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock worth $1,030,000 after purchasing an additional 1,277 shares during the period. Fred Alger Management LLC increased its stake in shares of Pfizer by 7.4% in the 3rd quarter. Fred Alger Management LLC now owns 102,668 shares of the biopharmaceutical company’s stock valued at $2,971,000 after acquiring an additional 7,076 shares during the last quarter. Tradition Wealth Management LLC raised its position in shares of Pfizer by 4.5% in the 3rd quarter. Tradition Wealth Management LLC now owns 25,358 shares of the biopharmaceutical company’s stock valued at $734,000 after acquiring an additional 1,099 shares during the period. Bellevue Group AG grew its holdings in Pfizer by 59.2% during the third quarter. Bellevue Group AG now owns 141,075 shares of the biopharmaceutical company’s stock valued at $4,083,000 after purchasing an additional 52,461 shares during the period. Finally, Semmax Financial Advisors Inc. raised its holdings in Pfizer by 3.2% in the third quarter. Semmax Financial Advisors Inc. now owns 101,267 shares of the biopharmaceutical company’s stock worth $2,695,000 after purchasing an additional 3,185 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Up 0.8 %

Shares of Pfizer stock opened at $25.20 on Monday. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The business’s 50 day moving average is $26.06 and its 200-day moving average is $26.90. The stock has a market cap of $142.93 billion, a P/E ratio of 17.87, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period in the prior year, the firm posted $0.10 earnings per share. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PFE. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. UBS Group decreased their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Bank of America reissued a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Citigroup cut their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.06% of the stock is currently owned by company insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.